Clinical trials: Other Metabolic Diseases
Schizophrenia, Schizoaffective Disorder
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288353
- Testing
- aripiprazole (Abilify), ziprasidone (Geodon)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Northwestern University
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26…
- Trial name
- DUAL™ II China (NCT03175120)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 37 sites in China, Hong Kong
- Volunteers
- 453 people
- Sponsor
- Novo Nordisk A/S
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Diabetes Mellitus, Type 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie…
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NBC (NCT03132571)
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizo-affective Disorder, Bipolar Disorder
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
The purpose of this study is to assess the efficacy of oral glycine as an augmentation strategy in two psychotic patients with a triplication (4 copies) of the gene glycine decarboxylase (GLDC).
- Trial name
- NCT01720316
- Testing
- Glycine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Psychosis, Schizophrenia
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- NCT03943537
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
Atypical antipsychotic medications, such as olanzapine, cause metabolic side effects, including weight gain, extra fat around the middle of the body, high blood sugar, and high cholesterol.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity
- Trial name
- NCT00512070
- Testing
- olanzapine and melatonin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Schizophrenia, Schizoaffective Disorder
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular…
- Trial name
- CAMP (NCT00423878)
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- 28 sites in United States
- Volunteers
- 215 people
- Sponsor
- National Institute of Mental Health (NIMH)
MPS IV A
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
- Trial name
- NCT01275066
- Testing
- BMN 110 Weekly, BMN 110 Every Other Week
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 177 people
- Sponsor
- BioMarin Pharmaceutical
Obesity, Schizophrenia
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
The purpose of this clinical trial is to find out how effective low dose oral naltrexone is on reducing body weight when compared to placebo in women with schizophrenia and schizoaffective disorder.
- Conditions
- Obesity, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00793780
- Testing
- Naltrexone 25mg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Type 1 Diabetes, Latent Autoimmune Diabetes in Adults
Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes
The challenges of living with type 1 diabetes often stand in the way of getting enough exercise. Continuous blood sugar monitoring has revolutionized type 1 diabetes care but remains underutilized to sustainably support exercise…
- Conditions
- Type 1 Diabetes, Latent Autoimmune Diabetes in Adults, Pancreatitis
- Trial name
- NCT06098729
- Testing
- Digital Exercise
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Diabetes, Asthma
Integrated Care (IC) Models for Patient-Centered Outcomes
Multiple chronic conditions (MCC) are widely recognized as the U.S. public health challenge of the 21st century. These physical and behavioral health conditions take a large toll on those living with chronic diseases, including…
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension
- Trial name
- IC (NCT03451630)
- Testing
- High-Touch, High-Tech, Optimal Discharge Planning
- Where
- United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Mental Health, Psychotic Disorders
Monitoring and Management for Metabolic Side Effects of Antipsychotics
The purpose of this study is to test an approach for implementing guideline recommendations for assessing and managing metabolic side effects (including weight gain, diabetes, elevated lipids) in patients prescribed antipsychotic…
- Trial name
- AMMP (NCT01875861)
- Testing
- Evidence-Based Quality Improvement Plus Facilitation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Arterial Embolization, Other Surgical Procedures
Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically
The purpose of this pilot study is to achieve the collection of safety and efficacy data in patients undergoing left gastric artery embolization for morbid obesity in the United States.
- Conditions
- Arterial Embolization, Other Surgical Procedures, Obesity
- Trial name
- GETLEAN (NCT02248688)
- Testing
- BeadBlock 300 - 500 Micron, Left Gastric Artery Embolization
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Dayton Interventional Radiology
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Schizoaffective Disorder
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study involves people who have schizophrenia or schizoaffective disorder who are currently taking antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00595504
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital